A 16-CpG-based Prognostic Signature for Colorectal Cancer

Abstract

Background: To develop a CpG-based prognostic prediction model to provide survival risk prediction for colorectal cancer. Differential methylation analysis was performed on 309 colorectal cancer and 38 adjacent cancer specimens from the Cancer Genome Atlas (TCGA). Results: 2113 hypermethylation sites as well as 723 hypomethylation sites were screened out and 16 related CpG methylation loci were further identified. The risk score was calculated based on the methylation sites identified and utilized as an independent prognostic variable for multivariate Cox regression prediction model, which was further optimized by the independent prognostic factors (including stage and risk score). Conclusion: This study has identified several potential prognostic biomarkers and established a CpG-based prognostic prediction model for colorectal cancer, which provides a valuable reference for future clinical research.